Coronaviruses can cause illness in people all around the world. They typically cause respiratory infections ranging from the common cold to more serious diseases like middleeast respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), and infectious disease. Molnupiravir is the first orally available medicine to immediately inhibit SARS-CoV-2 and has the potential to be used for treatment of covid 19. Molnupiravir has a high safety profile, tolerability, and oral bioavailability in humans. Molnupiravir may be available in a patient-friendly oral dose form in the first or second quarter of 2022. Early treatment with molnupiravir lowered the risk of hospitalization or death. Various antiviral drugs that are used for COVID-19 treatment are given in this review. We have also explained the various studies related to molnupiravir that could help researchersin finding the effectiveness of molnupiravir.